These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25035170)

  • 1. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma.
    Lebdai S; Verhoest G; Parikh H; Jacquet SF; Bensalah K; Chautard D; Rioux Leclercq N; Azzouzi AR; Bigot P
    Urol Oncol; 2015 Feb; 33(2):69.e11-8. PubMed ID: 25035170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of transforming growth factor beta induced (TGFBI) as an immune-related prognostic factor in clear cell renal cell carcinoma (ccRCC).
    Du GW; Yan X; Chen Z; Zhang RJ; Tuoheti K; Bai XJ; Wu HH; Liu TZ
    Aging (Albany NY); 2020 May; 12(9):8484-8505. PubMed ID: 32406866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma.
    Yang J; Liu P; Tian M; Li Y; Chen W; Li X
    Int J Oncol; 2013 Jun; 42(6):2078-86. PubMed ID: 23588948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
    Du P; Ye L; Yang Y; Jiang WG
    Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer.
    Boguslawska J; Kedzierska H; Poplawski P; Rybicka B; Tanski Z; Piekielko-Witkowska A
    J Urol; 2016 Jun; 195(6):1892-902. PubMed ID: 26631499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
    Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker.
    Qi Y; Zhang Y; Peng Z; Wang L; Wang K; Feng D; He J; Zheng J
    J Cell Mol Med; 2018 Feb; 22(2):1224-1235. PubMed ID: 29239102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ΑB-crystallin in clear cell renal cell carcinoma: tumor progression and prognostic significance.
    Ho PY; Chueh SC; Chiou SH; Wang SM; Lin WC; Lee IL; Yang HY; Peng HC; Lai MK
    Urol Oncol; 2013 Oct; 31(7):1367-77. PubMed ID: 22417627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma.
    Khella HW; Scorilas A; Mozes R; Mirham L; Lianidou E; Krylov SN; Lee JY; Ordon M; Stewart R; Jewett MA; Yousef GM
    Am J Pathol; 2015 Mar; 185(3):693-703. PubMed ID: 25572155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma.
    White NM; Masui O; Desouza LV; Krakovska O; Metias S; Romaschin AD; Honey RJ; Stewart R; Pace K; Lee J; Jewett MA; Bjarnason GA; Siu KW; Yousef GM
    Oncotarget; 2014 Jan; 5(2):506-18. PubMed ID: 24504108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.
    Wuttig D; Zastrow S; Füssel S; Toma MI; Meinhardt M; Kalman K; Junker K; Sanjmyatav J; Boll K; Hackermüller J; Rolle A; Grimm MO; Wirth MP
    Int J Cancer; 2012 Sep; 131(5):E693-704. PubMed ID: 22213152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative proteomic profiling identifies potential prognostic factors for human clear cell renal cell carcinoma.
    Sun X; Zhang H; Luo L; Zhong K; Ma Y; Fan L; Fu D; Wan L
    Oncol Rep; 2016 Dec; 36(6):3131-3138. PubMed ID: 27748938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
    Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
    BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas.
    Allory Y; Matsuoka Y; Bazille C; Christensen EI; Ronco P; Debiec H
    Clin Cancer Res; 2005 Feb; 11(3):1190-7. PubMed ID: 15709188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of β-catenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma.
    Krabbe LM; Westerman ME; Bagrodia A; Gayed BA; Darwish OM; Haddad AQ; Khalil D; Kapur P; Sagalowsky AI; Lotan Y; Margulis V
    J Urol; 2014 Jun; 191(6):1671-7. PubMed ID: 24291548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.
    Schrödter S; Braun M; Syring I; Klümper N; Deng M; Schmidt D; Perner S; Müller SC; Ellinger J
    Mol Cancer; 2016 Feb; 15():10. PubMed ID: 26831905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.